Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight

Celgene (NASDAQ: CELG) will co-develop three cell therapies for cancer with Immatics, a German biotech with ties to MD Anderson Center Center in Houston. Celgene will pay Immatics $75 million in cash up front to start the deal.